Health Care Equipment Equities under the Scanner - Medtronic, Abbott Laboratories, Stryker, Zeltiq Aesthetics, and EnteroMedics

Editor Note: For more information about this release, please scroll to bottom.

LONDON, September 26, 2014 /PRNewswire/ --

On Thursday, September 25, 2014, the NASDAQ Composite ended at 4,466.75, down 1.94%, the Dow Jones Industrial Average finished the day 1.54% lower at 16,945.80, and the S&P 500 closed at 1,965.99, down 1.62%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 743.47, down 1.58%, while the index has advanced 1.48% in the last one month. Investor-Edge has initiated coverage on the following equities: Medtronic Inc. (NYSE: MDT), Abbott Laboratories (NYSE: ABT), Stryker Corporation (NYSE: SYK), Zeltiq Aesthetics Inc. (NASDAQ: ZLTQ), and EnteroMedics Inc. (NASDAQ: ETRM). Free research on these five companies can be accessed at:  

http://investor-edge.com/register

On Thursday, Medtronic Inc.'s stock recorded a trading volume of 10.55 million shares, higher than its three months average volume of 7.74 million shares. The stock finished the day at $62.75, down 1.60%, and registered an intraday range of $62.74 and $64.32. Medtronic Inc.'s shares have declined 1.38% in the last one month and 2.26% in the past three months. However, the stock has surged 9.34% on YTD basis. Furthermore, the company's stock is trading above its 200-day moving average. The stock's 50-day moving average of $63.61 is above its 200-day moving average of $60.56. Additionally, shares of Medtronic Inc. traded at a PE ratio of 16.13 and have a Relative Strength Index (RSI) of 43.43. Sign up and read the free notes on MDT at:

www.Investor-Edge.com/MDT-26Sep2014

Shares in Abbott Laboratories fell 1.48%, to close Thursday's session at $42.00, after oscillating between $41.97 and $42.48. The stock recorded a trading volume of 4.30 million shares, below its three months average volume of 4.74 million shares. Over the last one month, shares of Abbott Laboratories have lost 1.15%. However, over the past three months and from the beginning of 2014, the stock has advanced 3.19% and 9.57%, respectively. The company's stock is trading above its 200-day moving average. The stock's 50-day moving average of $42.52 is above its 200-day moving average of $39.83. Further, Abbott Laboratories's stock traded at a PE ratio of 24.72 and has an RSI of 48.53. The complimentary notes on ABT can be downloaded as in PDF format at:

www.Investor-Edge.com/ABT-26Sep2014

On Thursday, Stryker Corp.'s stock finished the session 1.10% lower at $81.23. A total of 2.10 million shares were traded, which was above its three months average volume of 1.24 million shares. The stock moved between $80.93 and $82.16 during the session. Over the last one month and past three months, Stryker Corp.'s shares have declined by 2.05% and 4.99%, respectively. However, the stock has gone up 8.10% since the start of this year. The company's shares are trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $81.92 is greater than its 200-day moving average of $80.59. Shares of Stryker Corp. traded at a PE ratio of 19.42 and have an RSI of 44.68. Register for free on Investor-Edge and access the latest research on SYK at:

www.Investor-Edge.com/SYK-26Sep2014

Zeltiq Aesthetics Inc.'s stock fluctuated between $22.37 and $23.67 before ending Thursday's session down 3.80%, at $22.56. The stock reported a trading volume of 0.56 million shares, below its three months average volume of 0.74 million shares. Further, Zeltiq Aesthetics Inc.'s shares have rallied 10.48% over the last one month and 40.74% over the past three months. Also, the stock has surged 19.30% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $20.55 is greater than its 200-day moving average of $18.66. Moreover, shares of Zeltiq Aesthetics Inc. have an RSI of 54.53. The complete research on ZLTQ is available for free at:

www.Investor-Edge.com/ZLTQ-26Sep2014

Shares in EnteroMedics Inc. declined 3.45%, to close Thursday's session at $1.12, hitting a new 52-week low of $1.11. The stock recorded a trading volume of 0.54 million shares, below its three months average volume of 0.80 million shares. Over the last one month and past three months, EnteroMedics Inc.'s shares have lost 21.68% and 31.29%, respectively. Also, from the beginning of 2014, the stock has plummeted 45.10%. The company's stock is trading below its 50-day and 200-day moving averages. The stock's 200-day moving average of $1.83 is above its 50-day moving average of $1.38. Further, EnteroMedics Inc.'s stock has an RSI of 36.78. Free in depth research on ETRM is available at:

www.Investor-Edge.com/ETRM-26Sep2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Investor-Edge

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.